Comparison of depression and anxiety in inflammatory bowel patients treated with anti-TNF or immune modulators

Esra Çataltepe; Nergis Ekmen; Mehmet Cindoruk

Makale detayları

Comparison of depression and anxiety in inflammatory bowel patients treated with anti-TNF or immune modulators

Yazarlar:

Esra Çataltepe | Nergis Ekmen | Mehmet Cindoruk

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Health Care Administration

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.40 Issue 1, pp.47-51

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001285205

pISSN:

1309-4483

Anahtar kelimeler:

Özet:

 The aim of this study was to investigate patients diagnosed with inflammatory bowel disease IBD, the effects of drug groups used in the treatment of inflammatory bowel disease on depression and anxiety. This study was a single-center prospective study involving 94 patients with inflammatory bowel disease, 51 of whom had ulcerative colitis UC and 43 had Crohns disease CD. Harvey-Bradshaw activity scores for CD and Mayo Clinic activation scores for UC were calculated. Depression and anxiety data were collected with the Beck Depression Inventory and Beck Anxiety Inventory. The mean age for UC and CD were 40.25  14 and 38.9  13.8 years, respectively. There was a positive correlation between disease activation and depression and anxiety levels in both IBD subgroups p0.05. All patients included in the study were compared in terms of depression and anxiety levels before and after treatment, and a statistically significant improvement was found with the remission of both ulcerative colitis and Crohns disease p0.001. There was a significant difference in depression and anxiety levels before and after treatment according to treatment options p0.001. There is a positive relationship between the disease activation score and the level of depression and anxiety in IBD. Immunosuppressive and immunomodulatory drugs used in the treatment of IBD may also improve the parameters of depression and anxiety in this disease.

 The aim of this study was to investigate patients diagnosed with inflammatory bowel disease IBD, the effects of drug groups used in the treatment of inflammatory bowel disease on depression and anxiety. This study was a single-center prospective study involving 94 patients with inflammatory bowel disease, 51 of whom had ulcerative colitis UC and 43 had Crohns disease CD. Harvey-Bradshaw activity scores for CD and Mayo Clinic activation scores for UC were calculated. Depression and anxiety data were collected with the Beck Depression Inventory and Beck Anxiety Inventory. The mean age for UC and CD were 40.25  14 and 38.9  13.8 years, respectively. There was a positive correlation between disease activation and depression and anxiety levels in both IBD subgroups p0.05. All patients included in the study were compared in terms of depression and anxiety levels before and after treatment, and a statistically significant improvement was found with the remission of both ulcerative colitis and Crohns disease p0.001. There was a significant difference in depression and anxiety levels before and after treatment according to treatment options p0.001. There is a positive relationship between the disease activation score and the level of depression and anxiety in IBD. Immunosuppressive and immunomodulatory drugs used in the treatment of IBD may also improve the parameters of depression and anxiety in this disease.

 The aim of this study was to investigate patients diagnosed with inflammatory bowel disease IBD, the effects of drug groups used in the treatment of inflammatory bowel disease on depression and anxiety. This study was a single-center prospective study involving 94 patients with inflammatory bowel disease, 51 of whom had ulcerative colitis UC and 43 had Crohns disease CD. Harvey-Bradshaw activity scores for CD and Mayo Clinic activation scores for UC were calculated. Depression and anxiety data were collected with the Beck Depression Inventory and Beck Anxiety Inventory. The mean age for UC and CD were 40.25  14 and 38.9  13.8 years, respectively. There was a positive correlation between disease activation and depression and anxiety levels in both IBD subgroups p0.05. All patients included in the study were compared in terms of depression and anxiety levels before and after treatment, and a statistically significant improvement was found with the remission of both ulcerative colitis and Crohns disease p0.001. There was a significant difference in depression and anxiety levels before and after treatment according to treatment options p0.001. There is a positive relationship between the disease activation score and the level of depression and anxiety in IBD. Immunosuppressive and immunomodulatory drugs used in the treatment of IBD may also improve the parameters of depression and anxiety in this disease.

 The aim of this study was to investigate patients diagnosed with inflammatory bowel disease IBD, the effects of drug groups used in the treatment of inflammatory bowel disease on depression and anxiety. This study was a single-center prospective study involving 94 patients with inflammatory bowel disease, 51 of whom had ulcerative colitis UC and 43 had Crohns disease CD. Harvey-Bradshaw activity scores for CD and Mayo Clinic activation scores for UC were calculated. Depression and anxiety data were collected with the Beck Depression Inventory and Beck Anxiety Inventory. The mean age for UC and CD were 40.25  14 and 38.9  13.8 years, respectively. There was a positive correlation between disease activation and depression and anxiety levels in both IBD subgroups p0.05. All patients included in the study were compared in terms of depression and anxiety levels before and after treatment, and a statistically significant improvement was found with the remission of both ulcerative colitis and Crohns disease p0.001. There was a significant difference in depression and anxiety levels before and after treatment according to treatment options p0.001. There is a positive relationship between the disease activation score and the level of depression and anxiety in IBD. Immunosuppressive and immunomodulatory drugs used in the treatment of IBD may also improve the parameters of depression and anxiety in this disease.

Makale detayları

Comparison of depression and anxiety in inflammatory bowel patients treated with anti-TNF or immune modulators

Yazarlar:

Esra Çataltepe | Nergis Ekmen | Mehmet Cindoruk

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Health Care Administration

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.40 Issue 1, pp.47-51

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001285205

pISSN:

1309-4483

ulcerative colitis

crohn disease

depression

anxiety

disease activation

Sayı

Makale detayları

Comparison of depression and anxiety in inflammatory bowel patients treated with anti-TNF or immune modulators

Yazarlar: Esra Çataltepe | Nergis Ekmen | Mehmet Cindoruk

Yayıncı: Ondokuz Mayıs University

Ana Başlıklar: Health Care Administration

Dergi: Deneysel ve Klinik Tıp Dergisi Vol.40 Issue 1, pp.47-51

Belge Tipi: Makale

Yayın Tarihi: 3/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001285205

pISSN: 1309-4483

ulcerative colitis

crohn disease

depression

anxiety

disease activation

Sayı

Yazarlar:

Esra Çataltepe | Nergis Ekmen | Mehmet Cindoruk

Yayıncı:

Ondokuz Mayıs University

Ana Başlıklar:

Health Care Administration

Dergi:

Deneysel ve Klinik Tıp Dergisi Vol.40 Issue 1, pp.47-51

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001285205

pISSN:

1309-4483